Impact of sample size on the performance of multiple-model pharmacokinetic simulations

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 11, 2006, Pages 3950-3952

  Tam, Vincent H ^a   Kabbara, Samer ^a   Yeh, Rosa F ^a   Leary, Robert H ^b,c  

^a UNIVERSITY OF HOUSTON   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c PHARSIGHT CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

AREA UNDER THE CURVE; ARTICLE; DRUG EXPOSURE; MONTE CARLO METHOD; PHARMACOKINETICS; PREDICTION; PRIORITY JOURNAL; SAMPLE SIZE; SIMULATION;

ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; HUMANS; MONTE CARLO METHOD; PHARMACOKINETICS; POPULATION; SAMPLE SIZE;

EID: 33750578696     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00337-06     Document Type: Article

References (11)

1. Ambrose, P. G., S. M. Bhavnani, and R. N. Jones. 2003. Pharmacokinetics-pharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum β-lactamases: report from the ARREST program. Antimicrob. Agents Chemother. 47:1643-1646.
2. Drusano, G. L., S. L. Preston, C. Hardalo, R. Hare, C. Banfield, D. Andes, O. Vesga, and W. A. Craig. 2001. Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint. Antimicrob. Agents Chemother. 45:13-22.
3. Jelliffe, R., D. Bayard, M. Milman, M. Van Guilder, and A. Schumitzky. 2000. Achieving target goals most precisely using nonparametric compartmental models and "multiple model" design of dosage regimens. Ther. Drug Monit. 22:346-353.
4. Kuti, J. L., P. K. Dandekar, C. H. Nightingale, and D. P. Nicolau. 2003. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem. J. Clin. Pharmacol. 43:1116-1123.
5. Kuti, J. L., N. R. Florea, C. H. Nightingale, and D. P. Nicolau. 2004. Pharmacodynamics of meropenem and imipenem against Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa. Pharmacotherapy 24:8-15.
6. Kuti, J. L., C. H. Nightingale, and D. P. Nicolau. 2004. Optimizing pharmacodynamic target attainment using the NYSTIC antibiogram: data collected in North America in 2002. Antimicrob. Agents Chemother. 48:2464-2470.
7. Leary, R., R. Jelliffe, A. Schumitzky, and M. Van Guilder. 2001. Presented at the 14th IEEE Symposium on Computer-Based Medical Systems, Bethesda, Md., 26 to 27 July 2001.
8. Lodise, T. P., Jr., B. Lomaestro, K. A. Rodvold, L. H. Danziger, and G. L. Drusano. 2004. Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation. Antimicrob. Agents Chemother. 48:4718-4724.
9. Lomaestro, B. M., and G. L. Drusano. 2005. Pharmacodynamic evaluation of extending the administration time of meropenem using a Monte Carlo simulation. Antimicrob. Agents Chemother. 49:461-463.
10. Tam, V. H., A. Louie, B. M. Lomaestro, and G. L. Drusano. 2003. Integration of population pharmacokinetics, a pharmacodynamic target, and microbiologic surveillance data to generate a rational empiric dosing strategy for cefepime against Pseudomonas aeruginosa. Pharmacotherapy 23:291-295.
11. Tam, V. H., S. L. Preston, and G. L. Drusano. 2003. Comparative pharmacokinetic analysis by standard two-stage method versus nonparametric population modeling. Pharmacotherapy 23:1545-1549.